uniQure (NASDAQ:QURE) Price Target Raised to $76.00 at Chardan Capital

uniQure (NASDAQ:QURE) had its target price increased by Chardan Capital from $35.00 to $76.00 in a research note published on Thursday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Several other research firms have also recently issued reports on QURE. Leerink Partners lifted their price objective on shares of uniQure from $48.00 to $68.00 and gave the company an “outperform” rating in a research report on Wednesday. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 target price for the company in a report on Thursday, August 14th. Cantor Fitzgerald set a $47.00 target price on shares of uniQure in a report on Wednesday, July 30th. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of uniQure in a report on Wednesday. Finally, Stifel Nicolaus raised their target price on shares of uniQure from $30.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, uniQure currently has an average rating of “Buy” and an average price target of $64.64.

uniQure Price Performance

NASDAQ QURE opened at $52.65 on Thursday. The stock has a market cap of $2.89 billion, a price-to-earnings ratio of -13.43 and a beta of 0.14. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. uniQure has a 12 month low of $4.45 and a 12 month high of $54.98. The company’s 50 day moving average is $16.65 and its two-hundred day moving average is $14.61.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.20. The firm had revenue of $5.26 million for the quarter, compared to analysts’ expectations of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. As a group, research analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of QURE. Tower Research Capital LLC TRC boosted its stake in uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after buying an additional 5,538 shares during the period. Mraz Amerine & Associates Inc. purchased a new position in uniQure during the first quarter worth $106,000. KLP Kapitalforvaltning AS purchased a new position in uniQure during the second quarter worth $117,000. Teacher Retirement System of Texas purchased a new position in uniQure during the second quarter worth $151,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in uniQure during the first quarter worth $152,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.